Search
Searching Content indexed under Food, Drugs, Healthcare, Life Sciences by Oblon, McClelland, Maier & Neustadt, L.L.P ordered by Published Date Descending.
Links to Result pages
 
1 2 3  
>>Next
 
Title
Country
Organisation
Author
Date
1
Specification Must Adequately Disclose The Claimed Invention To Avoid Invalidation For Lack Of Written Description
Claim 25 of Application No. 12/393,833, continued from the '803 application, also recited using random MPS to determine fetal aneuploidy.
United States
11 Sep 2019
2
Thinking Outside The (Utility Patent) Box – Don't Overlook Design Patent Protection In The Life Sciences
Design patents are very different from utility patents in that design patents only protect the ornamental features of an invention. In contrast to utility patents, the design is defined
United States
2 Sep 2019
3
Cannabis Patent Lawsuits Are Blazing—Why The Law Is So Hazy
There's no prohibition on patenting illegal substances; however, if marijuana is illegal under federal law, how can a patent holder enforce such a right?
United States
28 Aug 2019
4
Non-Limiting Clauses And Written Description Based On Substantially Equivalent Disclosure
Nalpropion Pharmaceuticals, Inc. v Actavis Laboratories FL, Inc (Fed. Cir. Aug. 15, 2019) is a precedential opinion written by Judge Lourie with Judge Wallach and a dissent from Judge Prost
United States
20 Aug 2019
5
An Approach To Pharma Life Cycle Management
Every innovative pharma company faces the same challenge, how to delay the patent cliff. The existence of the "skinny viii" (21 U.S.C. § 355(j)(2)(A)(viii)) makes developing additional FDA
United States
14 Aug 2019
7
Why Cannabis Patent Enforcement Is In The Weeds
The article "Why Cannabis Patent Enforcement is in the Weeds," written by Daniel Pereira and contributed to by summer associate Alec Royka, is featured by Managing Intellectual Property.
United States
11 Jul 2019
8
Four Decisions Designated Informative On 101: Positive Trend For Life Sciences?
In January, 2019, the USPTO issued new guidance about what constitutes an abstract idea that is ineligible for protection under Section 101.
United States
5 Jul 2019
9
"Statutory" Obviousness-Type Double Patenting for Pharma Patents?
In short, the bill presumes obviousness-type double patenting of any subsequent orange book listed patent and shifts the burden to the patentee to demonstrate otherwise.
United States
24 Jun 2019
10
Commercial Success Of Claimed Product Over Non-Infringing Competitive Products As Evidence Of Non-Obviousness
As discussed in the briefs courts should properly weigh the evidence of commercial success as well as other evidence.
United States
19 Jun 2019
11
Written Description In Provisional Application: Perdue Pharma L.P. v. Andrei Iancu.
Amneal Pharmaceuticals, LLC. filed two petitions for inter partes review of claims 1–13 and 16–19 of U.S. Patent No. 9,034,376 of Purdue Pharma L.P., P.F. Laboratories, Inc. and Purdue Pharmaceuticals L.P.
United States
30 May 2019
12
What You Say Can Hurt You
Often in writing applications there is a tendency to denigrate prior art techniques.
United States
23 May 2019
13
Patent Strategy And the Internet Of Medical Things
James Love wrote an article entitled "Patent Strategy and The Internet of Medical Things," featured in Med Device Online.
United States
20 May 2019
14
"[T]He Proper Application Of The Supreme Court's Alice Standard Is An Evolving And Sometimes Hazy Area Of Law"
Marijuana, for medical purposes and recreational purposes, is an area of great political, social and legal interest.
United States
2 May 2019
15
Cleveland Clinic - Another Black Eye For The Federal Circuit And Dissing The USPTO
The clinic has filed minerals patent on this invention in an attempt to find a claim the Federal Circuit would find to be patent ineligible.
United States
5 Apr 2019
16
Natural Alternatives - Claim Construction Defeats A 101 Challenge On The Pleadings
The district court's decision arouse out of a motion for judgment on the pleadings filed by Creative.
United States
27 Mar 2019
17
Biologic Patent Transparency Act - New Bill Aimed At Biologics
A bipartisan group of senators sponsored a bill this week—the Biologic Patent Transparency Act, S. 659—aimed at making patent information associated with biologics easier to identify and easing the approval process ...
United States
14 Mar 2019
18
No More IPRs From Generic Drug Makers?
The USPTO argues that a petitioner who has received a favorable final written decision in an IPR is estopped from reusing the same winning argument in a district court.
United States
26 Feb 2019
19
Bioisosterism, By Itself, May Not Be Sufficient Motivation To Modify A Lead Compound
In affirming the PTAB, the Federal Circuit also assumed for the purposes of its decision that compound 31 was an appropriate lead compound.
United States
15 Feb 2019
Links to Result pages
 
1 2 3  
>>Next